ArticleInfection and drug resistance2026
An AI-Driven Antimicrobial Resistance Surveillance Framework for Low-Resource Settings: A Pilot Study from Mogadishu, Somalia.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) constitutes a profound global health crisis, with profoundly disproportionate impacts in low-resource settings (LRS) and conflict-affected regions like Somalia. Traditional laboratory-based surveillance is largely unfeasible in these environments due to resource constraints. This study proposes and preliminarily evaluates an Artificial Intelligence (AI)-driven surveillance framework to predict multidrug resistance (MDR) using minimal, routinely available clinical metadata. Methods: A retrospective cross-sectional analysis was conducted using 262 curated clinical bacterial isolates from Mogadishu, Somalia. A Random Forest machine learning algorithm was trained using five basic variables (patient age, sex, isolated organism, ward, and specimen source) to predict MDR against five sentinel antibiotics. Phenotypic co-resistance was further evaluated using an undirected weighted network analysis. Results: The predictive model achieved an overall accuracy of 66.7% (95% CI: 52.1-79.2%) and an Area Under the Curve (AUC) of 0.607. Prioritizing its utility as an early-warning triage tool, the model demonstrated an exceptionally high sensitivity (recall) of 91.4%, effectively flagging the vast majority of MDR cases, with a specificity of 12.5%, a precision of 69.6%, an F1-score of 0.79, and a Matthews Correlation Coefficient (MCC) of 0.06. The low MCC indicates that, despite high sensitivity, overall discriminative agreement beyond chance was weak. Variable importance analysis revealed that microbiological factors (organism and specimen source) were the strongest predictors of resistance. Conversely, spatial features (hospital ward) lacked predictive value, indicating widespread transmission. Network analysis identified a fully connected co-resistance topology (degree centrality = 4) among all sentinel antibiotics. Conclusion: High-sensitivity AI models utilizing minimal metadata offer a potentially scalable triage-support approach for MDR surveillance in deeply resource-constrained health systems. Given the modest discriminatory performance, low specificity, small final analytical sample, and the absence of external validation, these findings should be interpreted as a preliminary proof-of-concept rather than evidence of a deployment-ready tool. The findings underscore critical, hospital-wide infection prevention and control (IPC) vulnerabilities and highlight the necessity of implementing digital epidemiological tracking, alongside external validation and benchmarking against alternative algorithms, to guide empiric therapy in East Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.